Based on the Smith & Nephew SNATS Inc stock forecast from 2 analysts, the average analyst target price for Smith & Nephew SNATS Inc is USD 28.23 over the next 12 months. Smith & Nephew SNATS Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Smith & Nephew SNATS Inc is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, Smith & Nephew SNATS Inc’s stock price was USD 25.93. Smith & Nephew SNATS Inc’s stock price has changed by +0.31% over the past week, -8.89% over the past month and +8.77% over the last year.
No recent analyst target price found for Smith & Nephew SNATS Inc
No recent average analyst rating found for Smith & Nephew SNATS Inc
Company Overview Smith & Nephew SNATS Inc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom. Read Less
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Manage...Read More
Frequently Asked Questions About Smith & Nephew SNATS Inc (SNN) Stock
Based on ratings from 2 analysts Smith & Nephew SNATS Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and 2 hold ratings.
SNN stock's dividend yield is 2.85%.
Our analysis grades SNN stock's dividend yield at B. This means that SNN stock's dividend yield is above 83% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this SNN may be a good dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for SNN is USD 28.23 over the next 12 months. The maximum analyst target price is USD 30.7 while the minimum anlayst target price is USD 27.
SNN stock's Price/Earning ratio is 27.50.
Our analysis grades SNN stock's Price / Earning ratio at D+. This means that SNN stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this SNN may be fairly valued for its sector
The last closing price of SNN's stock was USD 25.93.
The most recent market capitalization for SNN is USD 11.31B.
Based on targets from 2 analysts, the average taret price for SNN is projected at USD 28.23 over the next 12 months.
This means that SNN's stock price may go up by +8.88% over the next 12 months.
We can't find any ETFs which contains Smith & Nephew SNATS Inc's stock.
As per our most recent records Smith & Nephew SNATS Inc has 17,349 Employees.
Smith & Nephew SNATS Inc's registered address is Building 5, Watford, United Kingdom, WD18 8YE.
You can get more information about it from Smith & Nephew SNATS Inc's website at https://www.smith-nephew.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Smith & Nephew SNATS Inc (SNN) Stock
Based on ratings from 2 analysts Smith & Nephew SNATS Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and 2 hold ratings.
SNN stock's dividend yield is 2.85%.
Our analysis grades SNN stock's dividend yield at B. This means that SNN stock's dividend yield is above 83% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this SNN may be a good dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for SNN is USD 28.23 over the next 12 months. The maximum analyst target price is USD 30.7 while the minimum anlayst target price is USD 27.
SNN stock's Price/Earning ratio is 27.50.
Our analysis grades SNN stock's Price / Earning ratio at D+. This means that SNN stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Medical Devices sector in the NYE exchange.
Based on this SNN may be fairly valued for its sector
The last closing price of SNN's stock was USD 25.93.
The most recent market capitalization for SNN is USD 11.31B.
Based on targets from 2 analysts, the average taret price for SNN is projected at USD 28.23 over the next 12 months.
This means that SNN's stock price may go up by +8.88% over the next 12 months.
We can't find any ETFs which contains Smith & Nephew SNATS Inc's stock.
As per our most recent records Smith & Nephew SNATS Inc has 17,349 Employees.
Smith & Nephew SNATS Inc's registered address is Building 5, Watford, United Kingdom, WD18 8YE.
You can get more information about it from Smith & Nephew SNATS Inc's website at https://www.smith-nephew.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SNN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
